Retatrutide 10 mg

Retatrutide 10 mg is Hilma Biocare's triple-agonist peptide, supplied as a single lyophilised vial. It targets GIP, GLP-1 and glucagon receptors simultaneously, making it the most advanced molecule in the incretin class.

What Retatrutide Is

Retatrutide is a synthetic peptide that activates three metabolic receptors: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon. Most incretin drugs target one or two of these; retatrutide adds glucagon agonism, which increases energy expenditure as well as reducing appetite. That triple action is why it is studied for obesity and metabolic disease. The 10 mg vial is the standard research presentation.

The History of Retatrutide

Retatrutide was developed by Eli Lilly as a next-generation incretin after semaglutide and tirzepatide. A phase 2 trial published in the New England Journal of Medicine in 2023 reported substantial weight loss at 48 weeks, drawing intense interest from researchers and clinicians. It remains investigational, but it is widely regarded as a benchmark for triple-agonist design.

How It Works

Retatrutide binds GLP-1 and GIP receptors to slow gastric emptying, reduce appetite and improve glucose-dependent insulin secretion. The glucagon receptor component increases hepatic energy expenditure and fat oxidation. Together the three pathways produce greater weight loss than GLP-1 agonism alone. The peptide is long-acting and resistant to DPP-4 degradation, allowing infrequent administration in trials.

What the Research Shows

• A 2023 phase 2 trial reported large reductions in body weight at 48 weeks.
• Research shows the glucagon component increases energy expenditure.
• Triple agonism produces greater metabolic effects than single or dual agonists in trials.
• Gastrointestinal effects are the most commonly reported adverse events.

Research Context

The phase 2 retatrutide trial enrolled adults with obesity and reported weight reductions of up to around a quarter of body weight at the highest dose over 48 weeks. That result exceeded what had been seen with GLP-1 agonists alone and confirmed that glucagon agonism adds meaningful energy expenditure. Researchers have also examined effects on liver fat and glycaemic markers. Gastrointestinal adverse effects were common, as with other incretins, and the compound remains investigational pending larger trials. The phase 2 data also showed dose-dependent improvements in fasting glucose and glycated haemoglobin, which is why the molecule is being studied in both obesity and type 2 diabetes.

Strength, Pack and Authentication

Each vial contains 10 mg of lyophilised retatrutide, sealed and packed in a printed carton stating the compound, strength and vial count. A scratch-off security code inside the box links the pack to Hilma Biocare's records. The powder is stable before reconstitution and intended for research use only.

Buying Retatrutide Online

Retatrutide is one of the most searched metabolic peptides. If you are researching retatrutide 10 mg, comparing triple agonists or looking to buy retatrutide online from a trusted Hilma Biocare supplier, this page gives you the full specification, pack size, price and live stock status. Browse more Hilma Biocare metabolic peptides at NotNatty.